Average and incremental cost effectiveness ratios from EPIC trial (Australian $)
| Abcixmab | Placebo | Incremental analysis | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Avg cost | Effect | Avg C/E | Avg cost | Effect | Avg C/E | Incr cost | Incr effect | Incr C/E | |||
| Composite end point | $8019 | 0.73 | $10 985 | $6965 | 0.649 | $10 732 | $1054 | 0.081 | $13 012 | ||
| Any revascularisation | $8019 | 0.773 | $10 374 | $6965 | 0.706 | $9865 | $1054 | 0.067 | $15 731 | ||
| Risk/benefit measure | $8019 | 0.714 | $11 231 | $6965 | 0.64 | $10 883 | $1054 | 0.074 | $14 243 | ||
Avg, average; C/E, cost effectiveness; Effect, effectiveness; Incr, incremental. The effectiveness measures represents the chance of being free from events.